ADA 2021: Novo trumpets higher-dose Ozempic data as Lilly competitors loom

And patients with baseline A1C of at least 9% saw reductions of 2.6%, versus 2.3% among patients on the lower dose. Weight loss favored the higher ...

from Google Alert - How to lose weight https://ift.tt/3w3xZdL